Nature of change: Reappointment as an Independent Director for a second term.
Name and DIN: Mr. Udo Jahannes Vetter (DIN: 00707474).
Effective date and tenure: Effective from July 21, 2026, for a term of five consecutive years until July 20, 2031.
Brief profile: Mr. Vetter earned his degree in Clinical Pharmacy from the University of Washington. He worked for five years as a Manufacturing Pharmacist at Schering Plough Corp. (now Merck & Co., Inc.), responsible for establishing production facilities in Puerto Rico. From 1985 to 1988, he served as Vice President, Licensing & Production, at Martec Inc., a generic pharmaceutical manufacturer. He was President of the start-up company Vetter Pharma-Turm Inc. in Pennsylvania, USA. From 1987 to 1991, he served as Managing Director of Vetter Pharma and subsequently as Managing Director of Vetter Inject GmbH & Co. KG from 1989 to 2003. Between 1999 and 2004, he was a member of the Executive Committee of Vetter Pharma Corporation. Since 1999, he has been a member of the Board of Managing Director of UV-Cap. He currently serves as Chairman of the ITM Group, Germany. He is a member of the International Society for Pharmaceutical Engineering (ISPE) and the Global Pharmaceutical Manufacturing Leadership Forum (GPMLF). He served as President of the European Family Businesses (EFB) Association for six years and now serves as its Vice-President. He served as Chairman of the University Council of the University of Albstadt-Sigmaringen until 2018 and was awarded the title of Honorary Senator.
Remuneration: Payment of commission on profits as remuneration, approved by shareholders.
Relationship with other directors: Not Applicable.
Eligibility confirmation: The reappointment is in terms of Section 149 of the Companies Act, 2013.
Appointment of Mr. William Robert Keller
Nature of change: Appointment as an Independent Director.
Name and DIN: Mr. William Robert Keller (DIN: 11593622).
Effective date and tenure: Effective from June 15, 2026, for a term of five consecutive years until June 14, 2031.
Brief profile: Mr. Keller, aged 78, is currently an Independent Director of Wuxi Biologics (a global CRDMO listed on the Hong Kong Stock Exchange) and Hua Medicine (listed on the Hong Kong Stock Exchange). From August 2020 to August 2025, he was a Director of Cathay Biotech Inc. (listed on the Shanghai Stock exchange). He was the Chairman of Coland Pharmaceutical Co. Ltd (formerly listed on the Taiwan Stock Exchange) for ten years until November 2020. From December 2009 to May 2015, he was an Independent Director of Alexion Pharmaceuticals Inc. (Nasdaq listed). Until December 2014, he was an Independent Director of Taigen Biopharmaceutical Holding Limited (Taiwan Stock Exchange listed). He has over 40 years of experience managing operations in South America and Asia in the pharmaceutical and biotechnology sectors. He spent almost three decades in management positions with Roche in South America and Asia, serving as Managing Director of Roche Hong Kong (1990-1994) and General Manager for Roche China Holding and Shanghai Roche Pharmaceutical Ltd. (1994-2003). In 2003, he founded Keller Pharma Consultancy, a pharmaceutical consulting firm. From June 1997 to December 2013, he served as Vice Chairman of the Shanghai Association of Enterprises with Foreign Investment. From March 2003 to June 2014, he was Deputy General Manager of Shanghai Zhangjiang Biotech and Pharmaceutical Base Development Co. Ltd. From March 2003 to December 2013, he served as a Senior Consultant of the Shanghai Foreign Investment Development Board. From May 2007 to April 2010, he served as Chairman of HBM Biomed China Partners Ltd. He holds a Bachelor of Science degree from the School of Economics and Business Administration in Zurich, Switzerland (July 1972).
Remuneration: Payment of commission on profits as remuneration, approved by shareholders.
Relationship with other directors: Not Applicable.
Eligibility confirmation: The appointment is in terms of Section 149 of the Companies Act, 2013.
